Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
33.96 USD +2.23% Intraday chart for Beam Therapeutics Inc. -2.61% +24.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency MT
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency CI
Transcript : Beam Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:35 PM
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk MT
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup DJ
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating MT
Beam Therapeutics Shares Jump on Surprise Q4 Profit MT
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading MT
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto MT
North American Morning Briefing : Microsoft Kicks -2- DJ
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38 MT
Transcript : Beam Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM
Beam Therapeutics Inc. Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones CI
North American Morning Briefing : Stock Futures -2- DJ
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35 MT
Beam Therapeutics Inc. Appoints Christi Shaw to Its Board of Directors CI
North American Morning Briefing : Investors Await -2- DJ
Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75 MT
Beam Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stocks Look to -2- DJ
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading MT
Eli Lilly to Acquire Beam Therapeutics' Opt-In Rights to Verve Therapeutics' Cardiovascular Programs MT
Chart Beam Therapeutics Inc.
More charts
Beam Therapeutics Inc. is a biotechnology company engaged in providing life-long cures to patients suffering from serious diseases. The Company operates a fully integrated platform for precision genetic medicines. Its base editing technology enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company is advancing its base editing technology across three disease-area portfolios: hematology, immunology/oncology and genetic diseases. Its clinical-stage programs include BEAM-101, BEAM-201, BEAM-301 and BEAM-302. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy designed to offer a profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin (HPFH). BEAM-201 is a development candidate comprised of T cells.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
33.96 USD
Average target price
49.62 USD
Spread / Average Target
+46.10%
Consensus
  1. Stock
  2. Equities
  3. Stock Beam Therapeutics Inc. - Nasdaq
  4. News Beam Therapeutics Inc.
  5. Beam Therapeutics : Unveils $260 Million Private Share Placement